|Articles|January 2, 2009

The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan

Dr. A. Mark Fendrick explains the concept of Value-Based Insurance Design (VBID) and how it works.

Our Co-Editor-in-Chief, Dr. A. Mark Fendrick, explains the concept of Value-Based Insurance Design (VBID) and discusses the implications of reducing co-pays for employers and insurers.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

The Oncology Care Model: A Decade of Transformation

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

The Co-Pay Connection - Dr. A. Mark Fendrick of the University of Michigan

Related Content

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD

UCART22 Advances to Phase 2 Following Encouraging Phase 1 Results in R/R B-Cell ALL: Nitin Jain, MD

The Oncology Care Model: A Decade of Transformation

Trending on AJMC

emtelligent Turns Unstructured Clinical Data Into Actionable Insights

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Real-World Data Show MASH Progresses Faster Than Trials Suggest